Metten Somers is a psychiatrist and Medical Director of the Mood and Psychosis Unit of the Department of Psychiatry at the UMC Utrecht. He was involved in the OPTiMISE trial as project manager and obtained his PhD on the relationship between language lateralization and left-handedness using psychiatric genetic and neuroimaging techniques. He holds an executive MBA degree from the Rotterdam School of Management, Erasmus University. His clinical and research work focuses on treatment resistant mood and psychotic disorders. His interest in psychedelics in psychiatry resulted in his involvement as site-PI in the trial ‘Psilocybin in Treatment Resistant Depression’, the first international large scale multicenter randomized clinical trial investigating the effectiveness and safety of psilocybin in depression. He is currently involved in several psychedelic related research initiatives, including setting up the follow-up phase III trial on psilocybin in treatment resistant depression. He is a co-founder and coordinator of the Psychedelics in Psychiatry Platform of the Dutch Association for Psychiatry.